Endocrine Abstracts

Introduction: Daily administration of Pegvisomant normalizes IGF1 levels >71% of acromegalics (1). Few studies have assessed the efficacy of weekly administration. We assessed the efficacy of weekly pegvisomant for 12 months, after withdrawal of long-acting somatostatin analogs (SSA) in acromegalics previously controlled on combination therapy.Design: Fifteen subjects (8 males), age 58 (35–80) (median (range)) years on combination therapy of hig...

Objective: The objective of this study was to asses the quality of self-management in patients with primary and secondary adrenal insufficiency and to find patient-related factors that influence quality of self-management.Methods: The quantitative research was assessed by a questionnaire. Mainly focused topics were i) demographic data ii) daily medication intake iii) en route precautions and iv) dose adaptation during medical emergencies. One hundred and...

Purpose: Hypopituitarism is frequently associated with lifelong replacement therapy. However, it has been suggested that recovery from hypopituitarism after transsphenoidal surgery (TSS) for pituitary adenomas may occur during follow up. The aim of this study was to assess the frequency of hypothalamus-pituitary-adrenal (HPA) axis recovery after TSS in patients with non-functioning pituitary adenomas and acromegaly.Methods: Over the 3-year observational ...

Background: Of the currently available treatment regimes for acromegaly, pegvisomant (PEG-V) has the highest efficacy. During PEG-V treatment, GH serum levels increase. The exact mechanism behind this is remains unclear. It could be explained by an ultra-short feedback loop via GH receptors in the anterior pituitary gland.Objective: To assess the level of GH receptor (GHR) mRNA expression in somatotroph adenomas and to evaluate whether GHR blockade by PE...